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radial distances were compared to those of the clinically 
used contours (inter-observer) and the average contours per 
patient and observer (intra-observer). The registration 
process was initiated with the localization of gold fiducial 
markers (FMs) and, if necessary, adjusted manually for 
rotation and/or translation. Prostate V100 and D90 were 
determined for each contour and registration. The two 
dosimetric parameters (DPs) were scaled with the patients 
clinical DPs (inter, see Figure 1) or the patients average per 
observer (intra) to remove the natural variation in DPs 
between patients. 
Results: Prostate contours on US resulted in an inter-observer 
variability of 1.1 mm (1 SD with respect to the clinical 
contours) and an intra-observer variability of 0.6 mm (1 SD 
with respect to the average contour per patient and 
observer). US-contouring alone led to dosimetric differences 
of 1.6% of the clinical V100 and 9.3% of the clinical D90, and 
an intra-observer variability of 0.6% (V100) and 1.0% (D90). 
US-CBCT registrations varied within 2.0% of the clinical V100 
and 3.1% of the clinical D90. For MRI-CBCT registration, this 
was 1.3% and 2.1% respectively. The intra-observer 
variabilities of US-CBCT (V100: 0.9% and D90: 1.5%) and MRI-
CBCT (V100: 0.7% and D90: 1.0%) registration were smaller 
than the inter-observer variabilities. During registration, 
observers found 91% of the FMs on US, 100% on CBCT and 99% 
on MRI. 78% of the US-CBCT registrations were manually 
adjusted based on the urethra contours and iodine seeds. 
MRI-CBCT registrations were manually adjusted in 18% of the 
studies. 
 
 
Conclusions: US- and MRI-CBCT registrations showed little 
variability compared to the inter-observer variability in US-
contouring. Inter-observer contouring caused D90 variations 
of 9.3% from the clinical value. The intra-observer contouring 
variability was comparable to the registration variability. 
Good FM visibility on MRI scans resulted in small registration 
variabilities. The inferior FM visibility on US was compensated 
by the manual adjustment based on seeds and urethra.  
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Purpose/Objective: Evaluation of tolerance, early and late 
toxicity of HDR brachytherapy combined with interstitial 
hyperthermia (IHT) in patients treated for prostate cancer. 
Materials and Methods: 105 patients were treated for 
prostate cancer using HDRBT combined with IHT. 79 patients 
were treated fo primary prostate adenocarcinoma, and 26 
patients for local recurrence after previous definitive EBRT. 
The treatment of 76 patients consisted of external beam 
radiotherapy (EBRT) to the total dose of 50 Gy and HDRBT 
boost (21Gy in 2 fractions), 3 patients received HDRBT as a 
monotherapy to the total dose of 45 Gy in 3 fractions. 
Salvage HDRBT for local cancer recurrence was performed to 
the total dose of 30 Gy in 3 fractions. IHT was planned before 
each HDRBT fraction to the temperature of 40-43ºC for 60 
minutes. Toxicity was assessed according to Common Toxicity 
Criteria for Adverse Events version 4.03. 
Results: The median follow-up time was 26.4 months (range 
7 – 61 months). We didn't observe any grade 3 or higher 
gastrointestinal (GI) or genitourinary (GU) early toxicities. 
Early GU grade 1 and 2 toxicities were common, but only two 
patients (1,9%) experienced acute urethral stenosis and 
required temporary catheterisation (grade 2). Only two 
patients (1,9%) developed late grade 3 urinary tract 
obstruction with urinary retention, which required 
transurethral resection of the prostate (TURP). The incidence 
of grade 2 toxicity in this group of patients did not exceed 
30%. There were no late grade 2 or higher complications from 
the gastrointestinal tract. There were no statistically 
significant differences in early complications between the 
groups of patients treated with radical and salvage intent, 
except for haematuria (p <0.01) and rectal bleeding (p 
<0.01). 
Conclusions:The combination of HDRBT with IHT is well 
tolerated. The profile of early and late complications is 
acceptable, while the incidence of grade 3 toxicity remained 
within a few percent only. 
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Purpose/Objective: High Dose-Rate brachytherapy (HDRB) 
for the treatment of prostate cancer provides biochemical 
control comparable to other treatment modalities with the 
benefit of reducing dose to the OARs. Generally delivered in 
conjunction with external beam radiotherapy HDRB has the 
potential advantage of allowing dose escalation due to the 
high dose delivered during the treatment fraction. However, 
the wide ranges of fractionation regimes used in different 
centres make it difficult to establish clear guidelines for 
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organs-at-risk toxicity. This study was performed to assess 
the best dosimetric predictor of urethra strictures. 
Materials and Methods: Patients treated between 2001 and 
2013 at a single institution with HDRB were retrospectively 
analysed. The patients were all reviewed 6, 12, 18, 24 
months and then every year until 10 years after the 
treatment and data collected in a database. Clinical, 
demographic, dosimetric and urethral stricture factors were 
captured. We used urethra Dose Volume Histograms (DVH) 
metrics: D10% (Gy), D5%(Gy) and D30%(Gy). We converted 
doses from 3 different fractionation regimes (18 Gy in 3, 19 
Gy in 2 and 18 Gy in 2 fractions) into Biological Effective Dose 
(BED) with α/β = 5 Gy. Univariate and Multivariate logistic 
regression were used to evaluate factors predictive of 
urethral stricture after HDRB. 
Results: 
 
We analysed data from 249 patients, with a median follow-up 
of 7 years (1.4- 13.4 years). Urethra strictures were present 
in 25/249 (10%) patients, and the median time to onset 
stricture was about 1.5 years (1 month-7 years). 
On univariate analysis, BED10%(Gy) (OR = 1.05, p= 0.01), 
BED30%(Gy) (OR = 1.05, p= 0.02), and BED5%(Gy) (OR=1.05, 
p= 0.01) were significantly correlated to urethra stricture. 
The AUC of the resulting model was 0.62 in all cases, 
however calibration was always suboptimal. Calibration 
showed improvement when the dosimetric factors were 
associated to clinical factors despite their lower significance, 
such as use of neoadjuvant androgen deprivation (OR=0.5, 
protective factor) which was present in 232 patients (Figure 
1).  
Conclusions: Urethra DVH metrics are related to stricture, 
particularly the dose to small urethra volumes (D10%). 
However androgen deprivation acts as an important dose 
response modifier, pointing out the importance of integrating 
dosimetric and clinical information in order to have a better 
identification of the subgroup of patients at high risk of 
developing severe urinary toxicity after HDRB. 
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Purpose/Objective: To demonstrate the feasibility, safety 
and effectiveness of dose escalation to Dominant 
Intraprostatic Lesion (DIL) as defined on multiparametric MRI 
(mpMRI) with Real-Time MRI-TRUS fusion High-Dose-Rate 
(HDR) Brachytherapy 
Materials and Methods: 15 patients with intermediate-high 
risk Prostate cancer and visible dominant intra-prostatic 
nodule on mpMRI have been treated prospectively. The 
treatment consisted of combined MRI-TRUS fusion HDR-
brachytherapy (1 fraction of 1500 cGy) and Hypofractionated 
external beam (3750 cGy in 15 fractions) (BED: 265Gy). 
Prostate gland, DILs and Organs at risk (OARs) were 
delineated on MRI dataset, MRI-TRUS fusion performed and 
contoured structures transferred to the US dataset. 
The homogeneity parameters used for optimization aim were 
prostate-V100 > 98%, V150 of 25-33%, V200 < 8%, urethral 
Dmax < 115% and rectal D1cc < 70% of prescribed dose. 
Within these constraints, a dose of 1875 Gy was delivered to 
at least 98% of the DIL volume (V125%>98%)(BED: 351Gy) 
Results: Median age was 70 years, median prostate volume 
was 23.8 cc, median number of needles was 16 (13-18). Dose 
escalation to DIL was feasible in 14/15 patients (93%) without 
violating dosimetric constraints and 1 patient presented a 
minimal deviation of dosimetric restrictions. Median prostate 
V100, V150 and V200 were 98.2, 30.6 and 7.4% respectively. 
Median urethral Dmax was 114.1%, median rectal D1cc was 
62.8%. Median V100, V125, V150 and V200 to DIL were: 100, 
99, 78.5 and 20% respectively. 
With a median follow-up of 10 months (range 9-16), none of 
the patients developed acute urinary retention, only 2 
patients presented acute GU grade 2 toxicity, none of the 
patients developed chronic grade ≥2 toxicity. All patients 
returned to the pre-treatment IPSS level after 2 months of 
follow-up. 
In addition to standard PSA follow-up, response has been 
assessed by mpMRI at 12 months. All patients evaluated with 
MRI presented a complete response based on functional 
parameters. 
Conclusions: This study demonstrates that dose escalation to 
DIL with MRI/TRUS fusion guided HDR brachytherapy is 
feasible, longer follow-up will demonstrate the safety and 
efficacy of this procedure. 
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Purpose/Objective: External Beam Radiotherapy (EBRT) is 
considered the standard practice for localized prostate 
cancer. Although this, local relapses are not negligible and 
the ideal salvage treatment is not well-defined. We report 
our outcomes in terms of efficacy and safety of Salvage High-
Dose-Rate Brachytherapy (HDRB) for locally recurrent 
prostate cancer after definitive radiation therapy (RT). 
Materials and Methods: From august 2004 to July 2014 we 
retrospectively analyzed 60 patients (pts) undergoing HDR-BT 
after pathologic confirmation of locally recurrent disease. 
The median age at recurrence was 66 years (55-77) and, the 
median PSA was 4’13ng/ml (1’27-17). Gleason score and T 
scale were 7 and T2, respectively. Prescribed total dose was 
38Gy. Pts received 4 fractions of 9’5Gy with 2 implants 
separated 2 weeks. The 6% of pts received neoadjuvant 
hormonotherapy and, 11% received adjuvant hormonal 
